United Therapeutics Q1 revenue $506.9M (+10% YoY); Tyvaso sales up 39%

UNITED THERAPEUTICS Corp

2023-Q1 EPS reported $4.86 revenue$506,900,000

Net income $240.9M flat YoY; diluted EPS $4.86 vs $5.03.
Tyvaso franchise net sales $238.4M (+39%) driven by Tyvaso DPI launch and label expansion.
Treprostinil products grew 16% combined; Orenitram hit record revenue of $88.2M.
R&D expense rose 20% to $82.9M, primarily on TETON IPF studies.
Effective tax rate decreased to 17% from 22% due to excess share-based compensation benefits.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UNITED THERAPEUTICS Corp reported quarter ended March 31, 2023 results: revenue $506.9 million, net income $240.9 million, EPS $4.86 per diluted share.

Period: quarter ended March 31, 2023
Revenue: $506.9 million
Net income: $240.9 million
EPS: $4.86 per diluted share
Result: reported results

Exact text from the filing

Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

UNITED THERAPEUTICS Corp filing history →

Source: SEC EDGAR

accession 0001082554-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.